↓ Skip to main content

A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects

Overview of attention for article published in Journal of Cancer Research & Clinical Oncology, March 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#7 of 1,751)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news
4 news outlets
blogs
1 blog
twitter
5 tweeters
facebook
1 Facebook page
video
1 video uploader

Citations

dimensions_citation
116 Dimensions

Readers on

mendeley
123 Mendeley
Title
A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects
Published in
Journal of Cancer Research & Clinical Oncology, March 2009
DOI 10.1007/s00432-009-0562-z
Pubmed ID
Authors

Gary Deng, Hong Lin, Andrew Seidman, Monica Fornier, Gabriella D’Andrea, Kathleen Wesa, Simon Yeung, Susanna Cunningham-Rundles, Andrew J. Vickers, Barrie Cassileth

Abstract

Cancer patients commonly use dietary supplements to "boost immune function". A polysaccharide extract from Grifola frondosa (Maitake extract) showed immunomodulatory effects in preclinical studies and therefore the potential for clinical use. Whether oral administration in human produces measurable immunologic effects, however, is unknown.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 123 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 3%
Japan 1 <1%
France 1 <1%
Unknown 117 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 25 20%
Student > Master 20 16%
Other 14 11%
Student > Bachelor 13 11%
Student > Ph. D. Student 11 9%
Other 24 20%
Unknown 16 13%
Readers by discipline Count As %
Medicine and Dentistry 41 33%
Agricultural and Biological Sciences 19 15%
Biochemistry, Genetics and Molecular Biology 15 12%
Nursing and Health Professions 6 5%
Pharmacology, Toxicology and Pharmaceutical Science 6 5%
Other 18 15%
Unknown 18 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 46. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 October 2020.
All research outputs
#557,929
of 17,379,776 outputs
Outputs from Journal of Cancer Research & Clinical Oncology
#7
of 1,751 outputs
Outputs of similar age
#7,058
of 194,920 outputs
Outputs of similar age from Journal of Cancer Research & Clinical Oncology
#1
of 19 outputs
Altmetric has tracked 17,379,776 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,751 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,920 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.